Simplexa Bordetella Universal Direct Kit

Background

The World Health Organization estimates that there are 50 million whooping cough cases worldwide each year, resulting in 350,000 deaths. Pertussis, caused by Bordetella pertussis, can be detected among all age groups (e.g., neonates, children, adolescents and adults). While a great majority of these cases are caused by B. pertussis, up to 20% of cases are caused by Bordetella parapertussis, which can present clinically as a milder pertussis-like disease.

Why to choose it

A high-throughput, simplified workflow with broad coverage, including both B. pertussis and B. parapertussis, without DNA extraction that provides results in about an hour.

For use on

LIASION MDX

Benefits

Simple and Dependable Bordetella Testing

The Simplexa Bordetella Universal Direct assay provides results in about an hour direct from nasopharyngeal swabs without the need for DNA isolation.

Reliability

Reliable performance that you can count on

The Simplexa Bordetella Universal Direct assay has 98.5% and 100% sensitivity for B. pertussis and B. parapertussis respectively.

SIMPLEXA BORDETELLA UNIVERSAL DIRECT CLINICAL AGREEMENT 

The performance of the Simplexa Bordetella Universal Direct assay is comparable for either extracted and non-extracted nucleic acid methodology.

Ordering Info

Please click below for more information

SIMPLEXA BROCHURE

DiaSorin Molecular Menu